GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enlivex Therapeutics Ltd (NAS:ENLV) » Definitions » Shiller PE Ratio

ENLV (Enlivex Therapeutics) Shiller PE Ratio : (As of Mar. 03, 2025)


View and export this data going back to 2014. Start your Free Trial

What is Enlivex Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Enlivex Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Enlivex Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enlivex Therapeutics Shiller PE Ratio Chart

Enlivex Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Enlivex Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Enlivex Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Enlivex Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enlivex Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enlivex Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Enlivex Therapeutics's Shiller PE Ratio falls into.



Enlivex Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Enlivex Therapeutics's E10 for the quarter that ended in Sep. 2024 is calculated as:

For example, Enlivex Therapeutics's adjusted earnings per share data for the three months ended in Sep. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-0.12/133.0289*133.0289
=-0.120

Current CPI (Sep. 2024) = 133.0289.

Enlivex Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201412 -8.800 99.070 -11.816
201503 -9.200 99.621 -12.285
201506 -10.400 100.684 -13.741
201509 -10.000 100.392 -13.251
201512 -13.600 99.792 -18.130
201603 -12.800 100.470 -16.948
201606 -8.800 101.688 -11.512
201609 -11.360 101.861 -14.836
201612 -7.600 101.863 -9.925
201703 -6.400 102.862 -8.277
201706 -4.000 103.349 -5.149
201709 -2.560 104.136 -3.270
201712 5.520 104.011 7.060
201803 -3.280 105.290 -4.144
201806 -2.720 106.317 -3.403
201809 -2.800 106.507 -3.497
201812 -3.769 105.998 -4.730
201903 -5.920 107.251 -7.343
201906 -1.120 108.070 -1.379
201909 -0.230 108.329 -0.282
201912 -0.280 108.420 -0.344
202003 -0.070 108.902 -0.086
202006 -0.230 108.767 -0.281
202009 -0.160 109.815 -0.194
202012 -0.430 109.897 -0.521
202103 -0.190 111.754 -0.226
202106 -0.170 114.631 -0.197
202109 -0.190 115.734 -0.218
202112 -0.270 117.630 -0.305
202203 -0.450 121.301 -0.494
202206 -0.540 125.017 -0.575
202209 -0.310 125.227 -0.329
202212 -0.390 125.222 -0.414
202303 -0.390 127.348 -0.407
202306 -0.370 128.729 -0.382
202309 -0.320 129.860 -0.328
202312 -0.480 129.419 -0.493
202403 -0.220 131.776 -0.222
202406 -0.160 132.554 -0.161
202409 -0.120 133.029 -0.120

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Enlivex Therapeutics  (NAS:ENLV) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Enlivex Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Enlivex Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Enlivex Therapeutics Business Description

Traded in Other Exchanges
Address
14 Einstein Street, Ness Ziona, ISR, 7403618
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.